PET Imaging of Prostate Cancer: Other Tracers

Eric M. Rohren, Homer A. Macapinlac

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


There are significant limitations in the current options for imaging of patients with prostate carcinoma. Although fluorodeoxyglucose is the mainstay of clinical imaging, many other isotope and tracer combinations can be imaged with PET. One of the strengths of nuclear imaging lies in the variety of radiotracers capable of being imaged. In the last 15 years, various compounds have been studied in the hope of identifying the ideal imaging agent for prostate cancer. In this article, the use of imaging agents other than fluorodeoxyglucose, choline, and acetate is discussed.

Original languageEnglish (US)
Pages (from-to)185-192
Number of pages8
JournalPET Clinics
Issue number2
StatePublished - Apr 2009


  • Androgen receptors
  • Hypoxia
  • Methionine
  • PET/CT
  • Prostate cancer
  • Testosterone derivatives

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'PET Imaging of Prostate Cancer: Other Tracers'. Together they form a unique fingerprint.

Cite this